XOMA Corporation Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Royalty and Commercial Payment Purchase Agreements - Affitech (Details)

Royalty and Commercial Payment Purchase Agreements - Affitech (Details) - USD ($)		3 Months Ended		9 Months Ended		12 Months Ended
	Oct. 06, 2021	Sep. 30, 2024	Mar. 31, 2024	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023	Dec. 31, 2022	Apr. 01, 2024
Agreements
Payments of consideration under RPAs, AAAs and CPPAs				$ 37,000,000	$ 14,650,000
Contingent consideration under RPAs, AAAs and CPPAs		$ 4,000,000		4,000,000		$ 7,000,000
Receipts under RPAs, AAAs and CPPAs				26,263,000	$ 8,428,000
Short-term royalty and commercial payment receivables		12,682,000		12,682,000		$ 14,215,000
Income from purchased receivables under EIR Method, Short-Term				9,985,000
Affitech \| Commercial Payment Purchase Agreement
Agreements
Payments of consideration under RPAs, AAAs and CPPAs	$ 6,000,000.0		$ 6,000,000.0
Period from each royalty payment date payment is due						60 days
Maximum regulatory and commercial sales milestone payments	20,000,000.0
Acquisition of royalty and commercial payment receivables, Long-Term	14,000,000.0
Contingent consideration under RPAs, AAAs and CPPAs			0
Maximum commercial sales milestone payments	$ 12,000,000.0
Receipts under RPAs, AAAs and CPPAs				16,900,000
Recognition of contingent consideration, Short-Term				3,000,000.0
Recognition of contingent consideration, Long-Term						$ 6,000,000.0
Allowance for credit losses		0		0		0
Royalty and commercial payment receivable								$ 7,800,000
Income from purchased receivables under EIR Method, Short-Term		5,400,000		10,000,000.0
Affitech \| Commercial Payment Purchase Agreement \| United States
Agreements
Payments of consideration under RPAs, AAAs and CPPAs							$ 5,000,000.0
Affitech \| Commercial Payment Purchase Agreement \| Europe
Agreements
Payments of consideration under RPAs, AAAs and CPPAs							$ 3,000,000.0
Affitech \| Commercial Payment Purchase Agreement \| Faricimab (VABYSMO)
Agreements
Payments eligible to receive (as a percent)	0.50%
Commercial payment receivable term	10 years
Affitech \| Commercial Payment Purchase Agreement \| Regulatory milestones
Agreements
Contingent consideration under RPAs, AAAs and CPPAs	$ 8,000,000.0
Affitech \| Commercial Payment Purchase Agreement \| Sales-based milestones, first and second
Agreements
Contingent consideration under RPAs, AAAs and CPPAs			$ 0			$ 6,000,000.0
Affitech \| Commercial Payment Purchase Agreement \| Sales-based milestones, third
Agreements
Contingent consideration under RPAs, AAAs and CPPAs		3,000,000.0		3,000,000.0
Short-term royalty and commercial payment receivables		$ 3,000,000.0		$ 3,000,000.0